Learning to read again Study participant Sheila Irvine, a patient at Moorfields Eye Hospital, training with the PRIMA device. (Courtesy: Moorfields Eye Hospital) A tiny wireless implant inserted under ...
AndroGuider is a blog where you can scoop your daily need of tech information with some dose of special reviews and custom ...
Lumen Scientific, Inc., a clinical-stage medical technology company developing bioelectric therapies for retinal disease, today announced the first U.S. patient has been randomized in the i-SIGHT2 ...
Doris is an 86-year-old woman who has been experiencing blurred vision in the left eye for the past month. B. Assessment and diagnosis only; I refer for treatment. C. Assessment only; I refer for ...
Blind patients are actually able to have meaningful central vision restoration, which has never been done before. "Getting back the ability to read is a major improvement in their quality of life, ...
Researchers have successfully used artificial intelligence (AI) to predict which patients need treatment to stabilize their corneas and preserve their eyesight, in a study presented at the 43rd ...
Please provide your email address to receive an email when new articles are posted on . A 42-year-old man with no significant medical history was urgently referred to New England Eye Center in July ...
Patients taking Ozempic for diabetes or weight loss now face a newly recognized threat to their eyesight. Federal regulators ...
Age-related macular degeneration (AMD) is a common eye condition in older adults that can affect central vision. Geographic atrophy is an advanced form of AMD that causes permanent vision changes.
Neha Pathak, MD, FACP, DipABLM: Welcome to the WebMD Health Discovered Podcast. I'm Dr Neha Pathak, WebMD's Chief Physician Editor for Health and Lifestyle Medicine. Okay, right now millions of people ...
Headlines warning about “Ozempic blindness” may be frightening to the millions of people taking a GLP-1 drug to treat Type 2 diabetes or for weight loss. It's not an official diagnosis, but an ...